TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17377504
Drug: Tacrolimus (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (0.05 mg/kg/day)
Study: 9841603
Drug: Proton‐pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton‐pump inhibitor (omeprazole or lansoprazole), amoxicillin, and either clarithromycin or ecabet sodium
Study: 351716
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel administered extraamniotically
Study: 351716
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (i.v. oxytocin, 20% NaCl solution, Premarin, balloon catheter, Rivanol)
Study: 30264293
Drug: E6201, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6201, an intravenous MEK1 inhibitor
Study: 28603112
Drug: Safoof akseer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safoof akseer e jigar (test drug)
Study: 28603112
Drug: Interferon Alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon Alpha (control therapy)
Study: 25524478
Drug: Cetuximab with
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab with PX-866 (8 mg p.o. daily)
Study: 21220064
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for PTSD treatment
Study: 19736332
Drug: Antipyretic agents
Normalized name: ANTIPYRETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyretic agents (rectal diclofenac followed by oral ibuprofen or acetaminophen)
Study: 17577104
Drug: Azelnidipine 8
Normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine 8 to 16 mg (average 14.5 mg)
Study: 17577104
Drug: Amlodipine 2.5
Normalized name: amlodipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5 to 7.5 mg (average 4.9 mg)
Study: 9115054
Drug: Atorvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin treatment initiation
Study: 9115054
Drug: Atorvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin treatment discontinuation
Study: 3086023
Drug: Intravenous nutrition
Normalized name: Intravenous nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nutrition with hypertonic glucose at energy intakes of 6650 to 17,100 kJ/day
Study: 3086023
Drug: Intravenous nutrition
Normalized name: Intravenous nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nutrition with hypertonic glucose
Study: 19695405
Drug: Generic enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic enoxaparin 60 mg SC
Study: 19695405
Drug: Branded enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded enoxaparin 60 mg SC
Study: 16897979
Drug: S‐1 +
Normalized name: Tegafur/Gimeracil/Oteracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐1 + biweekly docetaxel (DOC) combination therapy
Study: 10757544
Drug: High-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat diet (39.5% calories as fat) with red wine (240 mL/d) for 30 days
Study: 10757544
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (27% calories as fat) with red wine (240 mL/d) for 30 days
Study: 1633702
Drug: Topical cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporin (CS) formulation (10%)
Study: 1633702
Drug: Flumethasone pivalate
Normalized name: Flumethasone Pivalate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumethasone pivalate (FP) formulation (0.02%)
Study: 26840505
Drug: Xanthohumol drink
Normalized name: Xanthohumol
DrugBank: Xanthohumol (DB15359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthohumol drink (12 mg XN/P/day)
Study: 24751788
Drug: Clonidine 1
Normalized name: apraclonidine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 1 μg/kg/hr
Study: 22952182
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (600 μg retinyl palmitate/d)
Study: 22952182
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (300 μg retinyl palmitate/d)
Study: 22952182
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A + zinc (10 or 20 mg zinc sulfate/d)
Study: 17285405
Drug: Intravenous-based (IV)
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous-based (IV) anesthesia with modified neurolept anesthesia (droperidol 0.2 mg/kg and pentazocine 0.15-0.3 mg/kg) and postoperative intravenous infusion of buprenorphine (20 µg/ml) via PCA pump.
Study: 17285405
Drug: Epidural-based (EPI)
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural-based (EPI) anesthesia with combined epidural analgesia and general anesthesia (sevoflurane and nitrous oxide) followed by epidural infusion of 0.125% bupivacaine and 5 µg/ml buprenorphine.
Study: 11851643
Drug: L-N(G)-monomethyl arginine
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-N(G)-monomethyl arginine (LNMMA) at doses of 0.1, 0.3, 1.0 and 3.0 mg kg‐1 min‐1
Study: 30921490
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD) in oral solution (Epidiolex, 100 mg/mL)
Study: 30921490
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of CBD
Study: 16933434
Drug: Conjoint group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint group treatment
Study: 16933434
Drug: Gender-specific group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender-specific group treatment
Study: 11402826
Drug: Topical dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide eye drops, 3 times daily for a mean follow up of 9 months
Study: 9364107
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group (N=15)
Study: 4035650
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AT III and Heparin
Study: 24643901
Drug: Heliox-driven bronchodilation
Normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heliox-driven bronchodilation therapy
Study: 24643901
Drug: Air-driven bronchodilation
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-driven bronchodilation therapy
Study: 18808627
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (control group, n = 23)
Study: 16160598
Drug: Acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (600 mg orally twice daily on the day before and the day of contrast administration)
Study: 16160598
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no acetylcysteine, saline 0.9% intravenously at 1 mL/kg/h for 12 hours before and after contrast administration)
Study: 16160598
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum creatinine >2.5 mg/dL
Study: 16160598
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum creatinine <2.5 mg/dL
Study: 9919322
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with Nortriptyline (NT)
Study: 9919322
Drug: Maintenance monthly
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance monthly IPT (combined with NT or placebo)
Study: 8787856
Drug: Temporary high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary high-dose rate 125I implant
Study: 8787856
Drug: Permanent low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Permanent low-dose rate 125I implant
Study: 30857609
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone 4 mg with ropivacaine 0.75% (3 ml) and saline (1 ml)
Study: 30857609
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 4 mg with perineural saline (1 ml)
Study: 30857609
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with perineural saline (1 ml) and intravenous saline (1 ml)
Study: 19475410
Drug: NaP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaP + laxative
Study: 17373902
Drug: Targeted or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted or biological therapies
Study: 17373902
Drug: Newer chemotherapeutic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer chemotherapeutic agents
Study: 14729785
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid (UA) administration
Study: 26711384
Drug: Limited margins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited margins IMRT with temozolomide chemotherapy
Study: 26711384
Drug: Routine margins
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine margins IMRT with temozolomide chemotherapy
Study: 23275036
Drug: Acetazolamide (AZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (AZ) 1,000 mg intravenous administration (single dose)
Study: 20644497
Drug: Lactobacillus crispatus
Normalized name: LACTOBACILLUS CRISPATUS
DrugBank: Lactobacillus crispatus strain CTV-05 (DB19093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus crispatus CTV‐05 (LACTIN‐V) administered by a vaginal applicator at 2 × 10 colony‐forming units (cfu)/dose for 5 days followed by weekly application for 2 weeks
Study: 8690121
Drug: GH +
Normalized name: Delsym Cough + Cold Daytime
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH + hCG protocol: 4 IU SC GH daily 8 days before and throughout the hCG phase
Study: 6791938
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment (25 mg x 4 daily)
Study: 31725142
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous (IV) tranexamic acid given 1 to 3 hours after delivery
Study: 26340264
Drug: DHA plus
Normalized name: PNV-DHA Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA plus EPA (2 g/day)
Study: 23657962
Drug: Olmesartan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan + Amlodipine (fixed combination)
Study: 23657962
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of Olmesartan + Amlodipine
Study: 23657962
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of Olmesartan + Amlodipine
Study: 11256536
Drug: ACE-inhibitor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitor therapy
Study: 8988997
Drug: Cocaine 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 0.50 mg/kg
Study: 3326689
Drug: Bay‐o‐1248 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bay‐o‐1248 (20 mg or 10 mg)
Study: 20423998
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg twice daily p.o. for a minimum of 14 days)
Study: 20423998
Drug: Control (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (not receiving a Cox inhibitor)
Study: 15370247
Drug: Chlorambucil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil 0.1 mg/kg/day indefinitely
Study: 15370247
Drug: Chlorambucil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil 0.1 mg/kg/day plus theophylline 200 mg bid, orally
Study: 24322182
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate 2 g/vitamin D₃ 1000 IU daily
Study: 21939611
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (olanzapine, risperidone, quetiapine)
Study: 20137765
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (IG, Lantus)
Study: 20137765
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (ID, Levemir)
Study: 20137765
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (ID)
Study: 16029567
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg/kg intravenous injection
Study: 28860128
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 μg/kg/min)
Study: 26817183
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A split injection sites
Study: 26817183
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A non-split injection sites
Study: 9106936
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg anti-TNF-alpha moab
Study: 9106936
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg anti-TNF-alpha moab
Study: 19216705
Drug: Bepotastine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepotastine 10 mg OD tablet
Study: 11583747
Drug: Invasive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive therapy (revascularisation)
Study: 3284400
Drug: Fentanyl transdermal
Normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl transdermal patches (F-TTS) 75 micrograms/h
Study: 3284400
Drug: Fentanyl transdermal
Normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl transdermal patches (F-TTS)
Study: 3284400
Drug: Fentanyl transdermal
Normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl transdermal patches (F-TTS) and Placebo
Study: 31343521
Drug: HIIT performed
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIIT performed thrice weekly (HIIT×3/wk)
Study: 31343521
Drug: HIIT performed
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIIT performed twice weekly (HIIT×2/wk)
Study: 31343521
Drug: HIIT performed
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIIT performed once weekly (HIIT×1/wk)
Study: 31343521
Drug: MICT performed
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MICT performed thrice weekly (MICT×3/wk)
Study: 21322021
Drug: Rotigotine (2-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine (2-16 mg/24 hr)
Study: 19818700
Drug: Acute painful
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute painful edematous stage treatment (surgery or conservative)
Study: 17268412
Drug: Pre-dosing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-dosing with 5 x 100 mg LU
Study: 17268412
Drug: Without pre-dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Without pre-dosing
Study: 17268412
Drug: One week
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One week after pre-dosing
Study: 17268412
Drug: Three weeks
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three weeks after pre-dosing
Study: 7560253
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg DHCl
Study: 7560253
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg PHCl
Study: 7560253
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg DHCl and 80 mg PHCl
Study: 2090337
Drug: 2.5% topical
Normalized name: BP 2.5% Topical Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% topical ocular phenylephrine hydrochloride
Study: 2090337
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical ocular phenylephrine hydrochloride
Study: 22449646
Drug: Medication switch
Normalized name: witch hazel Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication switch plus CBT
Study: 15871756
Drug: Intermittent Positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Positive Expiratory Pressure (PEP) therapy, n = 11
Study: 12477218
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (24 microg bid)
Study: 12477218
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (400 microg b.i.d.)
Study: 26577258
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (10 patients)
Study: 20925517
Drug: MAF (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAF (0.5% ophthalmic solution with retention-enhancing agent)
Study: 20925517
Drug: Moxi (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxi (0.5% ophthalmic solution)
Study: 19544682
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg diclofenac plus B vitamins (thiamine, pyridoxine, cyanocobalamin)
Study: 2181621
Drug: Enteric-coated naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated naproxen tablets
Study: 2181621
Drug: Plain naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain naproxen tablets
Study: 28701677
Drug: Tolvaptan in
Normalized name: Product containing tolvaptan in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan in addition to conventional diuresis therapy
Study: 28701677
Drug: Conventional diuresis
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diuresis therapy only (control group)
Study: 18191455
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment (assertive community treatment, psycho-educational multi-family groups, social skills training)
Study: 12828753
Drug: Lithium gluconate
Normalized name: lithium gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium gluconate 8% ointment
Study: 10900994
Drug: Self-selected treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-selected treatment clients
Study: 27330150
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of 2 g tranexamic acid (TA) diluted in 200 ml of saline
Study: 27330150
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of saline (placebo group)
Study: 27330150
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical administration (control group)
Study: 19854632
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS reminder
Study: 20529769
Drug: Candid #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candid #1 vaccine (Argentina)
Study: 20529769
Drug: USA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: USA vaccine
Study: 17036474
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (oral administration)
Study: 15707013
Drug: Telmisartan (20‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (20‐80 mg)
Study: 15707013
Drug: Enalapril (5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5‐10 mg)
Study: 11526531
Drug: Octreotide-LAR (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide-LAR (20 mg)
Study: 9031963
Drug: Continuous low
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous low dose estradiol released from a vaginal ring (Estring)
Study: 9031963
Drug: Estriol vaginal
Normalized name: estriol Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol vaginal cream (Synapause)
Study: 8428468
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg) by iv infusion every 6 hrs for four doses
Study: 3593895
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g daily) in elderly subjects
Study: 27390049
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of pidotimod
Study: 12920692
Drug: TNF inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitors (general)
Study: 10571597
Drug: Alosetron 1
Normalized name: alosetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 1 mg twice daily (n=319)
Study: 10571597
Drug: Mebeverine 135
Normalized name: mebeverine 135 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine 135 mg three times daily (n=304)